V. Kadir Kadhiresan, PhD, joined Johnson & Johnson Innovation – JJDC, Inc. (JJDC) in 2007 and focuses on investments in medical devices and digital health. Kadir has more than two decades of operational, investment and business development experience.
Based in Boston, Kadir works closely with Johnson & Johnson leadership to identify business needs and has responsibility for sourcing, investing and managing venture investment opportunities. He holds board seats for several JJDC portfolio companies. Some of his investments include Coherex Medical (Acquired by Biosense Webster/JNJ), Spinal Modulation (Acquired by St.Jude/ABT), Novocure (NASDAQ: NVCR), Torax Medical (Acquired by Ethicon/JNJ), Neotract (Acquired by Teleflex) and Inspire Medical Systems (NYSE: INSP).
Before joining JJDC, Kadir was head of Business Development at Guidant, Inc., now Boston Scientific, Inc., where he led several transactions to access novel medical device technologies.
Prior to entering business development, he led the research and development of multiple early-stage technologies and products in cardiac rhythm management and heart failure. Kadir was instrumental in the development of the cardiac resynchronization device for heart failure, now a multibillion dollar product. At Heart Rhythm Technologies, a subsidiary of Guidant, he led the development of an ablation technology for treatment of atrial fibrillation and raised venture financing for the project.
Kadir has more than 40 issued patents and several scientific manuscripts published in top peer-reviewed journals.
Kadir received a PhD and MS in Biomedical Engineering from the University of Michigan, Ann Arbor, an MBA from the Kellogg School of Management at Northwestern University, and a BS in Electrical Engineering from National Institute of Technology (REC), Trichy, India. Kadir was awarded the engineering alumni merit award from University of Michigan and serves on its biomedical engineering advisory board.